Bristol-Myers Gives FTC More Time To Review $74B Merger
Bristol-Myers Squibb Co. has reset the clock for the Federal Trade Commission to wrap up its initial review of the pharmaceutical giant's planned $74 billion pick up of Celgene Corp., saying...To view the full article, register now.
Already a subscriber? Click here to view full article